These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29984037)

  • 1. L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine.
    Akuzum B; Kim S; Nguyen TT; Hong J; Lee S; Kim E; Kim J; Choi Y; Jhun H; Lee Y; Kim H; Sohn DH; Kim S
    Immune Netw; 2018 Jun; 18(3):e19. PubMed ID: 29984037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
    Siddiqui MA; Perry CM
    Drugs; 2006; 66(9):1263-71; discussion 1272-3. PubMed ID: 16827602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
    Touze A; El Mehdaoui S; Sizaret PY; Mougin C; Muñoz N; Coursaget P
    J Clin Microbiol; 1998 Jul; 36(7):2046-51. PubMed ID: 9650960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
    Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
    Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
    J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing an HPV vaccine to prevent cervical cancer and genital warts.
    Bryan JT
    Vaccine; 2007 Apr; 25(16):3001-6. PubMed ID: 17289220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography.
    Baek JO; Seo JW; Kim IH; Kim CH
    Protein Expr Purif; 2011 Feb; 75(2):211-7. PubMed ID: 20716445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
    Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
    Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity.
    Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N
    Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
    Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
    Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type-specific and cross-reactive epitopes in human papillomavirus type 16 capsid proteins.
    Beiss BK; Heimer E; Felix A; Burk RD; Ritter DB; Mallon RG; Kadish AS
    Virology; 1991 Sep; 184(1):460-4. PubMed ID: 1714667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine.
    Deschuyteneer M; Elouahabi A; Plainchamp D; Plisnier M; Soete D; Corazza Y; Lockman L; Giannini S; Deschamps M
    Hum Vaccin; 2010 May; 6(5):407-19. PubMed ID: 20953154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
    Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
    Yan X; Wang D; Liang F; Fu L; Guo C
    Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
    Reisinger KS; Block SL; Lazcano-Ponce E; Samakoses R; Esser MT; Erick J; Puchalski D; Giacoletti KE; Sings HL; Lukac S; Alvarez FB; Barr E
    Pediatr Infect Dis J; 2007 Mar; 26(3):201-9. PubMed ID: 17484215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines.
    Mandic A
    J BUON; 2012; 17(3):422-7. PubMed ID: 23033276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral immunogenicity of human papillomavirus-like particles expressed in potato.
    Warzecha H; Mason HS; Lane C; Tryggvesson A; Rybicki E; Williamson AL; Clements JD; Rose RC
    J Virol; 2003 Aug; 77(16):8702-11. PubMed ID: 12885889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.